


Isoniazid

Cat. No.:	HY-B0329
CAS No.:	54-85-3
Molecular Formula:	C ₆ H ₇ N ₃ O
Molecular Weight:	137.14
Target:	Bacterial; Autophagy; Mitophagy; Antibiotic
Pathway:	Anti-infection; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (364.59 mM; Need ultrasonic)					
	H ₂ O : 33.33 mg/mL (243.04 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		7.2918 mL	36.4591 mL	72.9182 mL
5 mM			1.4584 mL	7.2918 mL	14.5836 mL	
10 mM		0.7292 mL	3.6459 mL	7.2918 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 150 mg/mL (1093.77 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity ^{[1][2][3][4]} .
In Vitro	<p>Isoniazid (INH) is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in <i>M. tuberculosis</i> is called KatG^[1].</p> <p>KatG couples the isonicotinic acyl with NADH to form isonicotinic acyl-NADH complex. This complex binds tightly to the enoyl-acyl carrier protein reductase known as InhA, thereby blocking the natural enoyl-AcpM substrate and the action of fatty acid synthase. This process inhibits the synthesis of mycolic acid, required for the mycobacterial cell wall. A range of radicals are produced by KatG activation of isoniazid, including nitric oxide, which has also been shown to be important in the action of another antimycobacterial prodrug PA-824^{[2][3]}.</p> <p>Isoniazid is bactericidal to rapidly dividing mycobacteria but is bacteriostatic if the mycobacteria are slow-growing^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Front Bioeng Biotechnol. 2022 Mar 17;10:826093.
- ACS Chem Biol. 2021 Dec 15.
- Biotechnol Bioeng. 2021 Sep 3.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Suarez, J., et al., An oxyferrous heme/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG). J Biol Chem, 2009. 284(11): p. 7017-29.
- [2]. Timmins, G.S., et al., Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2004. 48(8): p. 3006-9.
- [3]. Singh, R., et al., PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008. 322(5906): p. 1392-5.
- [4]. Ahmad, Z., et al., Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis, 2009. 200(7): p. 1136-43.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA